Please use this identifier to cite or link to this item:
標題: 人類鳥胺酸脫羧酶與抗酶抑制子抗酶結合位上對抗酶結合能力之探討
Functional characterication of the antizyme binding site on human ornithine decarboxylase and human antizyme inhibitor
作者: 劉儼嶔
Liu, Yen-Chin
關鍵字: ornithine decarboxylase
Antizyme inhibitor
出版社: 生命科學系所
引用: 蘇家暘,2007,探討人類鳥胺酸脫羧.第117 至140 處序列與抗.結合所扮演之 角色。 Albeck S, Dym O, Unger T, Snapir Z, Bercovich Z, Kahana C (2008) Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci 17(5): 793-802 Almrud JJ, Oliveira MA, Kern AD, Grishin NV, Phillips MA, Hackert ML (2000) Crystal structure of human ornithine decarboxylase at 2.1A resolution: structure insight to antizyme binding. J Mol Biol 295: 7-16 Auvinen M, Paasinen A, Andersson LC, Holtta E (1992) Ornithine decarboxylase activity is critical for cell transformation. Nature 360: 355-358 Balbo PB, Patel CN, Sell KG, Adcock RS, Neelakantan S, Crooks PA, Oliveira MA (2003) Spectrophotometric and steady-state kinetic analysis of the biosynthetic arginine decarboxylase of Yersinia pestis utilizing arginine analogues as inhibitors and alternative substrates. Biochemistry 42: 15189-15196 Balitskaia OV, Berdinskikh NK, Kononenko NG (1992) [The possibilities of using the free polyamines of the peripheral blood as biochemical tumor markers in nephroblastoma in children]. Vopr Onkol 38(6): 674-682 Bercovich Z, Kahana C (2004) Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme. J Biol Chem 279(52): 54097-54102 Brown PH, Schuck P (2006) Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J 90: 4651-4661 24 Chen H, MacDonald A, Coffino P (2002) Structure elements of antizymes 1 and 2 are required for proteasomal degradation of ornithine decarboxylase. J Biol Chem 277: 45957-45961 Choi KS, Suh YH, Kim WH, Lee TH, Jung MH (2005) Stable siRNA-mediated silencing of antizyme inhibitor: regulation of ornithine decarboxylase activity. Biochem Biophys Res Commun 328(1): 206-212 Coffino P (2001) Antizyme, a mediator of ubiquitin-independent proteasomal degradation. Biochimie 83: 319-323 Cohavi O, Tobi D, Schreiber G (2009) Docking of antizyme to ornithine decarboxylase and antizyme inhibitor using experimental mutant and double-mutant cycle data. J Mol Biol 390(3): 503-515 Daigle ND, Carpentier GA, Frenette-Cotton R, Simard MG, Lefoll MH, Noel M, Caron L, Noel J, Isenring P (2009) Molecular characterization of a human cation-Cl- cotransporter (SLC12A8A, CCC9A) that promotes polyamine and amino acid transport. J Cell Physiol 220(3): 680-689 Dayoub R, Thasler WE, Bosserhoff AK, Singer T, Jauch KW, Schlitt HJ, Weiss TS (2006) Regulation of polyamine synthesis in human hepatocytes by hepatotrophic factor augmenter of liver regeneration. Biochem Biophys Res Commun 345(1): 181-187 Fujita K, Murakami Y, Hayashi S (1982) A macromolecular inhibitor of the antizyme to ornithine decarboxylase. Biochem J 204: 647-652 Ghoda L, Phillips MA, Bass KE, Wang CC, Coffino P (1990) Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular 25 degradation. J Biol Chem 265(20): 11823-11826 Grishin NV, Osterman AL, Brooks HB, Phillips MA, Goldsmith EJ (1999) X-ray structure of ornithine decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with alpha-difluoromethylornithine. Biochemistry 38(46): 15174-15184(Ghoda et al, 1990) Hayashi S, Murakami Y (1995) Rapid and regulated degradation of ornithine decarboxylase. Biochem J 306: 1-10 Heller JS, Fong WF, Canellakis ES (1976) Induction of a protein inhibitor to ornithine decarboxylase by the end products of its reaction. Proc Natl Acad Sci USA 73: 1858-1862 Hoffman DW, Carroll D, Martinez N, Hackert ML (2005) Solution structure of a conserved domain of antizyme: a protein regulator of polyamines. Biochemistry 44(35): 11777-11785 Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, London WB, Buxton A, Gilmour SK, Marshall GM, Haber M (2008) ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68(23): 9735-9745 Holm I, Persson L, Stjernborg L, Thorsson L, Heby O (1989) Feedback control of ornithine decarboxylase expression by polyamines. Analysis of ornithine decarboxylase mRNA distribution in polysome profiles and of translation of this mRNA in vitro. Biochem J 258(2): 343-350 Hoshino K, Momiyama E, Yoshida K, Nishimura K, Sakai S, Toida T, Kashiwagi K, Igarashi K (2005) Polyamine transport by mammalian cells and mitochondria: 26 role of antizyme and glycosaminoglycans. J Biol Chem 280(52): 42801-42808 Howlett GJ, Minton AP, Rivas G (2006) Analytical ultracentrifugation for the study of protein association and assembly. Curr Opin Chem Biol 10: 430-436 Hua SB, Li X, Coffino P, Wang CC (1995) Rat antizyme inhibits the activity but does not promote the degradation of mouse ornithine decarboxylase in Trypanosoma brucei. J Biol Chem 270(17): 10264-10271 Ivanov IP, Rohrwasser A, Terreros DA, Gesteland RF, Atkins JF (2000) Discovery of a spermatogenesis stage-specific ornithine decarboxylase antizyme: antizyme 3. Proc Natl Acad Sci USA 97: 4808-4813 Jackson LK, Brooks HB, Osterman AL, Goldsmith EJ, Phillips MA (2000) Altering the reaction specificity of eukaryotic ornithine decarboxylase. Biochemistry 39: 11247-11257 Kitani T, Fujisawa H. (1989) Purification and characterization of antizyme inhibitor of ornithine decarboxylase from rat liver. Biochim Biophys Acta 991: 44-49 Keren-Paz A, Bercovich Z, Porat Z, Erez O, Brener O, Kahana C (2006) Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions. Oncogene 25: 5163-5172 Keren-Paz A, Bercovich Z, Kahana C (2007) Antizyme inhibitor: a defective ornithine decarboxylase or a physiological regulator of polyamine biosynthesis and cellular proliferation. Biochem Soc Trans 35(Pt 2): 311-313 Kern AD, Oliveira MA, Coffino P, Hackert ML (1999) Structure of mammalian ornithine decarboxylase at 1.6A resolution: stereochemical implications of 27 PLP-dependent amino acid decarboxylsae. Structure 7: 567-581 Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR (2006) Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism. J Cell Sci 119(Pt 12): 2583-2591 Li X, Coffino P (1992) Regulated degradation of ornithine decarboxylase requires interaction with the polyamine-inducible protein antizyme. Mol Cell Biol 12: 3556-3562 Li X, Coffino P (1993) Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein. Mol Cell Biol 13: 2377-2383 Lopez-Contreras AJ, Lopez-Garcia C, Jimenez-Cervantes C, Cremades A, Penafiel R (2006) Mouse ornithine decarboxylase-like gene encodes an antizyme inhibitor devoid of ornithine and arginine decarboxylating activity. J Biol Chem 281(41): 30896-30906 Mangold U, Leberer E (2005) Regulation of all members of the antizyme family by antizyme inhibitor. Biochem J 385(Pt 1): 21-28 Matsufuji S, Matsufuji T, Miyazaki Y, Murakami Y, Atkins JF, Gesteland RF, Hayashi S (1995) Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 80: 51-60. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, Tanaka K, Ichihara Akira (1992) Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360: 597-599 Nakagawa H, Kubo S, Murasawa A, Nakajima S, Nakajima Y, Izumoto S, Hayakawa 28 T (1992) Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors. J Neurooncol 12(2): 111-120 Nakazawa K, Nemoto T, Hata T, Seyama Y, Nagahara S, Sano A, Itoh H, Nagai Y, Kubota S (2007) Single-injection ornithine decarboxylase-directed antisense therapy using atelocollagen to suppress human cancer growth. Cancer 109(5): 993-1002 Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M, Finley D, Zetter BR. (2004) Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem 279: 41504-41511 Pegg AE (2006) Regulation of ornithine decarboxylase. J Biol Chem 281: 14529-14532 Raul F (2007) Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent. Biochem Soc Trans 35(Pt 2): 353-355 Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL (2009) Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69(2): 547-553 Saunders LR, Verdin E (2006) Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. Mol Cancer Ther 5(11): 2777-2785 Shantz LM, Coleman CS, Pegg AE (1996) Expression of an ornithine decarboxylase dominant-negative mutant reverses eukaryotic initiation factor 4E-induced cell transformation. Cancer Res 56: 5136-5140 29 Snapir Z, Keren-Paz A, Bercovich Z, Kahana C (2008) ODCp, a brain- and testis-specific ornithine decarboxylase paralogue, functions as an antizyme inhibitor, although less efficiently than AzI1. Biochem J 410(3): 613-619 Takao K, Rickhag M, Hegardt C, Oredsson S, Persson L (2006) Induction of apoptotic cell death by putrescine. Int J Biochem Cell Biol 38(4): 621-628 Tosaka Y, Tanaka H, Yano Y, Masai K, Nozaki M, Yomogida K, Otani S, Nojima H, Nishimune Y (2000) Identification and characterization of testis specific ornithine decarboxylase antizyme (OAZ-t) gene: expression in haploid germ cells and polyamine-induced frameshifting. Genes Cells 5: 265-276 Tsodikov, OV, Record, MT, Jr, Sergeev, YV (2002) Novel computer program for fast exact calculation of accessible and molecular surface areas and average surface curvature. J. Comput. Chem 23: 600–609 Valasinas A, Reddy VK, Blokhin AV, Basu HS, Bhattacharya S, Sarkar A, Marton LJ, Frydman B (2003) Long-chain polyamines (oligoamines) exhibit strong cytotoxicities against human prostate cancer cells. Bioorg Med Chem 11(18): 4121-4131 Wallace HM (2007) Targeting polyamine metabolism: a viable therapeutic/preventative solution for cancer? Expert Opin Pharmacother 8(13): 2109-2116 Wu F, Grossenbacher D, Gehring H (2007) New transition state-based inhibitor for human ornithine decarboxylase inhibits growth of tumor cells. Mol Cancer Ther 6(6): 1831-1839 Zhang M, MacDonald AI, Hoyt MA, Coffino P (2004) Proteasome begin ornithine decarboxylase digestion at the C terminus. J Biol Chem 279: 20959-20965 30 Zhang M, Pickart CM, Coffino P (2003) Determinants of proteasome recognition of ornithine decarboxyalse, a ubiquitin-independent substrate. EMBO J 22: 1488-1496 Zhu C, Lang DW, Coffino P (1999) Antizyme2 is a negative regulator of ornithine decarboxylase and polyamine transport. J Biol Chem 274: 26425-26430
摘要: 人類鳥胺酸脫羧酶(ornithine decarboxylase, ODC; EC 4. 1. 1. 17)是體內多 元胺(polyamines)生合成路徑中第一步驟與速率決定的酵素。ODC 為5’-磷酸 吡哆醛(PLP)依賴型酵素,催化過程結構上需形成雙聚體才能進一步催化鳥胺 酸(L-ornithine)釋出腐胺(putrescine)及CO2。ODC 為泛素(ubiquitination) 作用不依賴型酵素,抗酶(antizyme, AZ)能夠與鳥胺酸脫羧酶結合使其無法形 成雙聚體而失去其酵素活性,在細胞內與抗酶結合的鳥胺酸脫羧酶更容易被26S 蛋白酶體(proteasome)分解,而不需先與泛素結合。抗酶抑制子( Antizyme inhibitor, AZI)是序列及分子量都與鳥胺酸脫羧酶十分相似的蛋白質,但不具有 酵素活性。抗酶抑制子與抗酶的結合能力比鳥胺酸脫羧酶還強,能回復鳥胺酸脫 羧酶受抗酶抑制的情形。經序列比對,鳥胺酸脫羧酶與抗酶抑制子在抗酶結合位 上可能影響其結合能力的胺基酸有125、126、133、135、140 位置之不同。在活 性抑制的結果中,以ODC-N125K 及ODC-M140K 受抑制的情形較明顯,代表側 鏈上正電荷是決定鳥胺酸脫羧酶及抗酶抑制子與抗酶結合能力不同的關鍵。進一 步探討鳥胺酸脫羧酶突變型、抗酶抑制子突變型、抗酶三者間的交互作用,實驗 結果顯示突變型ODC-N125K 及ODC-M140K 與抗酶結合的親和性比鳥胺酸脫羧 酶野生型佳,突變型AZI-K125N 及AZI-K140M 則無法與鳥胺酸脫羧酶野生型競 爭抗酶,說明側鏈中的正電荷是影響與抗酶結合親和性的因素。探討ODC 與AZI 對AZ 的解離常數(Kd),結果顯示突變型ODC-N125K/ODC-M140K 的抗酶結合 親和性與抗酶抑制子野生型有相同程度的效果,證明正電荷為抗酶結合親和性的 影響關鍵因素。
Human ornithine decarboxylase (ODC; EC 4. 1. 1. 17) is the first and rate-limiting enzyme in the polyamine biosynthesis pathway. It is a pyridoxal 5'-phosphat (PLP)-dependent homodimeric enzyme that provides the only route for converting ornithine to putrescine and carbon dioxide. Antizyme (AZ) binds to ODC, inhibits ODC activity and promote the ubiquitin-independent degradation of ODC by 26S proteasome. Antizyme inhibitor (AZI) is highly homologous to ODC but is not enzymatically active. AZI, which has higher binding affinity to AZ, can rescue ODC from antizyme inhibition. Based on the sequence alignments of ODC and AZI, 125, 126, 133, 135, 140 residues are different in AZ-binding element between them. Our data indicated that the higher inhibited activities of ODC-N125K and ODC-M140K, which referred to the higher binding affinity to AZ, suggesting that the positive charge of side chain are crucial for AZ-binding affinity. Comparison with the dissociation constant of AZI-wt and ODC-N125K/M140K toward AZ, it indicated that ODC-N125K/M140K has a decreased Kd value similar to that of AZI, further supporting that the positive charge plays a crucial role in AZ-binding affinity.
其他識別: U0005-1707200915391700
Appears in Collections:生命科學系所



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.